Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low Following Weak Earnings

Sionna Therapeutics, Inc. (NASDAQ:SION) shares reached a new 52-week low during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $12.46 and last traded at $13.04, with a volume of 30317 shares traded. The stock had previously closed at $13.88.

The company reported ($3.38) EPS for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SION. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price for the company. TD Cowen assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating for the company. Finally, Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price objective for the company.

Sionna Therapeutics Price Performance

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.